Xuyong Wei

3.4k total citations
127 papers, 2.3k citations indexed

About

Xuyong Wei is a scholar working on Molecular Biology, Hepatology and Surgery. According to data from OpenAlex, Xuyong Wei has authored 127 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Molecular Biology, 47 papers in Hepatology and 33 papers in Surgery. Recurrent topics in Xuyong Wei's work include Liver Disease Diagnosis and Treatment (24 papers), Hepatocellular Carcinoma Treatment and Prognosis (21 papers) and Organ Transplantation Techniques and Outcomes (20 papers). Xuyong Wei is often cited by papers focused on Liver Disease Diagnosis and Treatment (24 papers), Hepatocellular Carcinoma Treatment and Prognosis (21 papers) and Organ Transplantation Techniques and Outcomes (20 papers). Xuyong Wei collaborates with scholars based in China, Madagascar and United States. Xuyong Wei's co-authors include Xiao Xu, Haiyang Xie, Shusen Zheng, Lin Zhou, Qi Ling, Di Lu, Shusen Zheng, Hangxiang Wang, Jianguo Wang and Jiaping Wu and has published in prestigious journals such as Advanced Materials, Angewandte Chemie International Edition and SHILAP Revista de lepidopterología.

In The Last Decade

Xuyong Wei

111 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xuyong Wei China 26 1.1k 605 464 463 414 127 2.3k
Han Wu China 31 808 0.8× 709 1.2× 330 0.7× 625 1.3× 533 1.3× 92 2.5k
Chuanrui Xu China 23 1.0k 1.0× 275 0.5× 552 1.2× 478 1.0× 283 0.7× 53 2.3k
Kaishan Tao China 31 1.5k 1.4× 422 0.7× 472 1.0× 921 2.0× 283 0.7× 108 2.9k
Yitao Ding China 30 1.3k 1.3× 305 0.5× 413 0.9× 895 1.9× 174 0.4× 63 2.3k
Wonhee Hur South Korea 26 997 0.9× 379 0.6× 131 0.3× 434 0.9× 407 1.0× 60 1.9k
Stefania Cannito Italy 29 872 0.8× 1.1k 1.8× 484 1.0× 582 1.3× 1.0k 2.4× 63 2.7k
Guihua Chen China 29 1.7k 1.6× 240 0.4× 390 0.8× 910 2.0× 239 0.6× 85 3.2k
Lixia Xu China 30 1.6k 1.6× 265 0.4× 258 0.6× 966 2.1× 245 0.6× 106 2.8k
Kim R. Bridle Australia 24 450 0.4× 577 1.0× 459 1.0× 170 0.4× 601 1.5× 64 2.4k
Seiki Tashiro Japan 24 536 0.5× 710 1.2× 744 1.6× 294 0.6× 358 0.9× 87 2.2k

Countries citing papers authored by Xuyong Wei

Since Specialization
Citations

This map shows the geographic impact of Xuyong Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xuyong Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xuyong Wei more than expected).

Fields of papers citing papers by Xuyong Wei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xuyong Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xuyong Wei. The network helps show where Xuyong Wei may publish in the future.

Co-authorship network of co-authors of Xuyong Wei

This figure shows the co-authorship network connecting the top 25 collaborators of Xuyong Wei. A scholar is included among the top collaborators of Xuyong Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xuyong Wei. Xuyong Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Xuanyu, Linping Cao, Zhe Yang, et al.. (2025). Post-Transplant Hepatitis B Virus Reactivation and Survival in Hepatocellular Carcinoma Patients with Alcoholic Liver Disease. Engineering. 49. 304–313.
2.
Chen, Jinyan, Zhigang Hu, Zuyuan Lin, et al.. (2025). Machine learning predicts post-transplant muscle loss in hepatocellular carcinoma patients without sarcopenia. BMC Cancer. 25(1). 1565–1565.
3.
Xiang, Ze, Jiarui Li, Jiong Yu, et al.. (2025). Impact of Donor CMV‐Seropostive Grafts on Prognosis of Liver Transplantation for Hepatocellular Carcinoma. Journal of Medical Virology. 97(1). e70150–e70150. 1 indexed citations
4.
Xiang, Ze, Jiarui Li, Shusen Zheng, et al.. (2025). Cell differentiation-related signaling pathways in hepatocellular carcinoma metastasis. Cancer Letters. 627. 217846–217846. 3 indexed citations
5.
Chen, Jinyan, Zhigang Hu, Jianyong Zhuo, et al.. (2025). HBV reactivation and its metabolomic profile after liver transplantation for hepatocellular carcinoma in non-alcoholic steatohepatitis. Chinese Journal of Cancer Research. 37(5). 865–878.
6.
Xu, Xiao, et al.. (2024). Genetic engineering drives the breakthrough of pig models in liver disease research. Liver Research. 8(3). 131–140. 6 indexed citations
7.
Xiang, Xiaonan, Kai Wang, Hui Zhang, et al.. (2024). Blocking CX3CR1+ Tumor-Associated Macrophages Enhances the Efficacy of Anti-PD1 Therapy in Hepatocellular Carcinoma. Cancer Immunology Research. 12(11). 1603–1620. 10 indexed citations
8.
Zhang, Hui, et al.. (2024). ZIP4 inhibits Ephrin-B1 ubiquitination, activating Wnt5A/JNK/ZEB1 to promote liver cancer metastasis. Genes & Diseases. 11(6). 101312–101312.
9.
Wang, Shuai, Lijun Meng, Huan Chen, et al.. (2024). Hepatocellular carcinoma-specific epigenetic checkpoints bidirectionally regulate the antitumor immunity of CD4 + T cells. Cellular and Molecular Immunology. 21(11). 1296–1308. 5 indexed citations
10.
Chen, Jinyan, Jianyong Zhuo, Zuyuan Lin, et al.. (2024). Impact of immunosuppressants on tumor pulmonary metastasis: new insight into transplantation for hepatocellular carcinoma. Cancer Biology and Medicine. 21(11). 1033–1049. 3 indexed citations
11.
Xiang, Ze, Jianrong Liu, Jiarui Li, et al.. (2024). Impact of preoperative infection on the outcomes of liver transplant recipients: a national propensity score-matched retrospective cohort study in China. International Journal of Surgery. 110(4). 2196–2206.
12.
Yang, Mengfan, Xiangyu Zhai, Xinyu Yang, et al.. (2024). Integrated multi-omic analysis identifies fatty acid binding protein 4 as a biomarker and therapeutic target of ischemia–reperfusion injury in steatotic liver transplantation. Cellular and Molecular Life Sciences. 81(1). 83–83. 5 indexed citations
13.
Wang, Shuai, Jianguo Wang, Yiyuan Chen, et al.. (2023). BMI1-induced CD127+KLRG1+ memory T cells enhance the efficacy of liver cancer immunotherapy. Cancer Letters. 571. 216336–216336. 12 indexed citations
14.
Zhang, Runnan, Shiqun Shao, Ying Piao, et al.. (2023). Esterase‐Labile Quaternium Lipidoid Enabling Improved mRNA‐LNP Stability and Spleen‐Selective mRNA Transfection. Advanced Materials. 35(46). e2303614–e2303614. 46 indexed citations
15.
Zhuo, Jianyong, Yiyuan Chen, Huan Chen, et al.. (2023). Downregulation of N4-acetylcytidine modification in myeloid cells attenuates immunotherapy and exacerbates hepatocellular carcinoma progression. British Journal of Cancer. 130(2). 201–212. 7 indexed citations
16.
Wang, Shuai, Rui Wang, Xuyong Wei, et al.. (2023). SULT2B1-CS-DOCK2 axis regulates effector T-cell exhaustion in HCC microenvironment. Hepatology. 78(4). 1064–1078. 33 indexed citations
17.
Zhuo, Jianyong, Di Lu, Jianguo Wang, et al.. (2021). Molecular phenotypes reveal heterogeneous engraftments of patient-derived hepatocellular carcinoma xenografts. Chinese Journal of Cancer Research. 33(4). 470–479. 10 indexed citations
18.
Zhuo, Jianyong, Di Lu, Zuyuan Lin, et al.. (2020). C C motif chemokine ligand 16 inhibits the progression of liver cirrhosis via inactivating hepatic stellate cells. Hepatobiliary & pancreatic diseases international. 19(5). 440–448. 13 indexed citations
19.
20.
Ling, Qi, Xiao Xu, Xuyong Wei, et al.. (2011). Oxymatrine induces human pancreatic cancer PANC-1 cells apoptosis via regulating expression of Bcl-2 and IAP families, and releasing of cytochrome c. Journal of Experimental & Clinical Cancer Research. 30(1). 66–66. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Han Wu Breakdown of academic impact, for papers by Chuanrui Xu Breakdown of academic impact, for papers by Kaishan Tao Breakdown of academic impact, for papers by Yitao Ding Breakdown of academic impact, for papers by Wonhee Hur Breakdown of academic impact, for papers by Stefania Cannito Breakdown of academic impact, for papers by Guihua Chen Breakdown of academic impact, for papers by Lixia Xu Breakdown of academic impact, for papers by Kim R. Bridle Breakdown of academic impact, for papers by Seiki Tashiro
Rankless by CCL
2026